Drotrecogin alfa (aktiveret) er ikke blevet undersøgt farmakokinetisk hos patienter med svær sepsis og eksisterende terminal nyresygdom eller kronisk leversygdom.
The pharmacokinetics of drotrecogin alfa (activated) have not been studied in patients with severe sepsis and pre-existing end stage renal disease and chronic hepatic disease.